Abstract
Objectives: There are conflicting reports on the role of cholesterol as an adverse prognostic predictor in patients with heart failure (HF). This study aimed to examine the impact of low levels of low-density lipoprotein cholesterol (LDL-c) on cardiac mortality in a cohort of elderly patients with moderate and severe HF. Methods: Chronic HF patients from the HF Unit at the Tel-Aviv Medical Center (n = 212, 77% males) with an average NYHA classification of 2.8, a mean age of 76.9 ± 7.3 years (range 66-91) and a mean follow-up of 3.7 years were consecutively enrolled. The cohort was divided into tertiles according to LDL-c levels: LDL <90 mg/dl (group 1), LDL 90-115 mg/dl (group 2) and LDL >115 mg/dl (group 3). Results: The Cox regression analysis revealed that group 3 patients had the best outcome (p = 0.01 vs. groups 2 and 3), with 58% of them surviving longer than 50 months compared to 34% in group 1. The same trend was seen in the group of patients suffering from ischemic cardiomyopathy and in patients who were treated by statins (p = 0.04). Conclusion: Low LDL-c levels are associated with a reduced survival in elderly patients with clinically controlled moderate and severe HF.
Journal Section:
Editor's choice
References
1.
Lenfant C: Report of the Task Force on Research in Heart Failure. Circulation 1994;90:1118-1123.
[PubMed]
2.
Cowie MR, Mosterd A, Wood DA, et al: The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
[PubMed]
3.
Ford I, Murray H, Packard CJ, Shepherd J, et al: West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486.
[PubMed]
4.
Pedersen TR, Olsson AG, Faergeman O, et al, Scandinavian Simavastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis 2004;5(suppl):81-87.
[PubMed]
5.
Raina A, Pickering T, Shimbo D: Statin use in heart failure: a cause for concern? Am Heart J 2006;152:39-49.
[PubMed]
6.
van der Harst P, Voors AA, van Gilst WH, et al: Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006;71:443-454.
[PubMed]
7.
Song XJ, Yang CY, Liu B, et al: Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci 2011;8:564-572.
[PubMed]
8.
Khush KK, Waters DD: Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail 2006;12:664-674.
[PubMed]
9.
Sakatani T, Shirayama T, Suzaki Y, et al: The association between cholesterol and mortality in heart failure. Comparison between patients with and without coronary artery disease. Int Heart J 2005;46:619-629.
[PubMed]
10.
von Haeling S, Okonko DO, Anker SD: Statins: a treatment option for chronic heart failure? Heart Fail Monit 2004;4:90-97.
[PubMed]
11.
Domanski M, Coady S, Fleg J, et al: Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 2007;99:1448-1450.
[PubMed]
12.
Iwaoka M, Obata JE, Abe M, et al: Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail 2007;13:247-253.
[PubMed]
13.
Afsarmanesh N, Horwich TB, Fonarow GC: Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006;152:1077-1083.
[PubMed]
14.
Christ M, Klima T, Grimm W, et al: Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2006;27:691-699.
[PubMed]
15.
Horwich TB, Hamilton MA, Maclellan WR, et al: Low serum cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224.
[PubMed]
16.
Rauchhaus M, Clarc AL, Doehner W, et al: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1940.
[PubMed]
17.
Flammer AJ, Sudano I, Wolfrum M, et al: Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J 2012;33:2172-2180.
[PubMed]
18.
Silva S, Lourenço P, Paulo C, et al: Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure. J Cardiovasc Pharmacol Ther 2012;17:284-290.
[PubMed]
19.
Aronov SW, Ahn C: Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;90:147-149.
[PubMed]
20.
Richartz BM, Radovancevic B, Frazier OH, et al: Low serum cholesterol levels predict high perioperative mortality in patients supported by left ventricular assist system. Cardiology 1998;89:184-188.
[PubMed]
21.
Fraunberger P, Nagel D, Walli AK, et al: Serum cholesterol and mortality in patients multiple organ failure. Crit Care Med 2000;28:3574-3575.
[PubMed]
22.
Liu Y, Caresh J, Eustace JA, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459.
[PubMed]
23.
Schatz U, Masaki K, Yano K, et al: Cholesterol and all-cause mortality in elderly people from Honolulu Heart Program: a cohort study. Lancet 2001;358:351-355.
[PubMed]
24.
Tikhonoff V, Casiglia E, Mazza A, et al: Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc 2005;53:2159-2164.
[PubMed]
25.
Anand IS, Latini R, Florea VG, et al, Val-HeFT Investigators: C-reactive protein in heart failure: prognostic value and effect of valsartan. Circulation 2005;112:1428-1434.
[PubMed]
26.
Charach G, George J, Afek A, et al: Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Cardiol 2010;105:100-104.
[PubMed]
27.
Harris HW, Grunfeld C, Feingold KR, et al: Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990;86:696-702.
[PubMed]
28.
Kjekshus J, Apetrei E, Barrios V, et al, CORONA Group: Rosuvastatin in older patients with systolic heart failure. NEJM 2007;357:1-14.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.
